By Brazil Stock Guide – Sanofi (Euronext: SAN; Nasdaq: SNY) is stepping up efforts to sell Medley, its Brazilian subsidiary, as it prepares to exit the local generics market. Executives from its Paris headquarters are in Brazil this week to advance talks, O Globo reported. Lazard is advising the process.
The sale, in the works since 2024, could fetch as much as US$1 billion, though market expectations point to bids closer to US$500 million to US$600 million. Sanofi bought Medley in 2009. Today it is Brazil’s second-largest generics manufacturer, with products ranging from antibiotics to blood-pressure treatments and painkillers.
Brazil’s generics market generates more than R$40 billion (US$7.3 billion) annually. It is expanding faster than branded medicines. Even so, tight price controls and falling margins have prompted global drugmakers to scale back.
EMS emerges as frontrunner
EMS is preparing a bid of about US$500 million, with formalization expected in January 2026, local media reported. Its plant in Hortolândia sits close to Medley’s facility in Campinas, offering logistical synergies. EMS also plans to keep the Medley brand alive in retail, competing alongside its own generics portfolio. If approved by antitrust regulator Cade, the deal would cement EMS’s lead and increase market concentration.
Other Brazilian players including Hypera (B3: HYPE3), Eurofarma, Aché and Neo Química have been cited as potential bidders. Analysts say their financial positions and strategic priorities make it hard to challenge EMS.
The sale marks a strategic pivot for Sanofi, which is shifting investments toward vaccines, oncology and immunology. It also highlights a broader retreat by multinational companies from a generics business that was once central, but now demands scale and strict cost control to sustain margins.
Leave a Reply